There's never been a good time to have a rare blood-based disorder, but there's also never been a better time than right now. That's because the U.S. Food and Drug Administration (FDA) has been unusually quick to review and approve new drug applications for treatments with life-saving potential for small groups of patients.
In the fourth quarter alone, the FDA approved three new drugs for people who inherited life-threatening blood disorders, months ahead of schedule. Here's why they could also become some of the most successful new drug launches of 2020.
Data source: U.S. Food and Drug Administration.